This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): BMS-562247, Erikyusu (Japan)
Description: Apixaban, a follow-on molecule to Razaxaban, acts as an anticoagulant by directly inhibiting coagulation factor Xa.
Bristol-Myers Squibb and DuPont
In 2001, Bristol-Myers Squibb acquired DuPont Pharmaceuticals from which it acquired a factor Xa drug.
Bristol-Myers Squibb and Pfizer
In April 2007, Bristol-Myers Squibb and Pfizer announced a worldwide collaboration to develop and commercialize apixaban. Terms of the apixaban agreement include an upfront payment of $250 million by Pfizer to Bristol-Myers Squibb. Pfizer will fund 60% of all planned development costs effective January 1, 2007 going forward, and Bristol-Myers Squibb will fund 40%. Bristol-Myers Squibb may also receive additional payments of up to $750 million based on development and regulatory milestones. The companies will jointly develop the clinical and marketing strategy of apixaban, and will share commercialization expenses and profits/losses equally on a global basis.
Portola, Bristol-Myers Squibb and Pfizer
In November 2012, Portola, Bristol-Myers Squibb and Pfizer announced a clinical...See full deal structure in Biomedtracker
Partners: Pfizer Inc.
Additional information available to subscribers only: